48 results
8-K
EX-10.1
XLO
Xilio Therapeutics Inc
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
, legal, regulatory, accounting, credit and tax matters. Neither such inquiries nor any other due diligence investigation conducted by such Investor
8-K
EX-99.1
s6t0f
3 Nov 23
Other Events
4:05pm
8-K
EX-10.1
rd49i 7s5
5 Sep 23
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
8:35am
8-K
EX-10.1
zo6lu2e7blos qyems
3 Aug 23
Departure of Directors or Certain Officers
4:15pm
S-3
EX-4.4
ygchan8p
9 Nov 22
Shelf registration
4:15pm
S-3
EX-1.2
tew7bgt87djxwqkvv4
9 Nov 22
Shelf registration
4:15pm
S-3
EX-4.5
y889aj5n 2xdld4
9 Nov 22
Shelf registration
4:15pm
8-K
EX-10.1
vw50mwrz hy
16 Jun 22
Departure of Directors or Certain Officers
7:45am